Azurity Pharmaceuticals Executive and Leadership Team

Ronald Scarboro, the Chief Executive Officer at Azurity Pharmaceuticals, directs the company's overall strategic vision and operational execution. Scarboro guides the organization's efforts to develop and deliver innovative, high-quality medicines, particularly for underserved patient populations. This leadership role involves overseeing the diverse portfolio across multiple therapeutic areas and dosage forms, ensuring alignment with the company's mission to improve patient outcomes. Scarboro's strategic direction leverages advanced commercial strategies, data, and digital tools to enhance market reach and patient engagement. The Chief Executive Officer's focus remains on addressing unmet medical needs and solidifying Azurity Pharmaceuticals' position as a leader in the biopharmaceutical sector. Ronald Scarboro's executive oversight ensures the company's continued growth and impact in the healthcare landscape.

Kenneth Bate, the President and Chief Executive Officer at Azurity Pharmaceuticals, spearheads the company's strategic direction and executive leadership. Bate drives the development and delivery of innovative, high-quality medicines, with a specific focus on serving underserved patient populations. This executive role encompasses the oversight of a diverse portfolio spanning multiple therapeutic areas and dosage forms, ensuring the company effectively addresses unmet medical needs. Bate's leadership integrates advanced commercial strategies, data analytics, and digital tools to optimize market reach and patient engagement. The President and Chief Executive Officer's mandate includes fostering a culture of innovation and operational excellence. Kenneth Bate's comprehensive management ensures Azurity Pharmaceuticals consistently enhances patient outcomes and strengthens its global market presence.

Tom Oneil, the Chief Financial Officer at Azurity Pharmaceuticals, manages the company's financial operations and strategic fiscal planning. Oneil oversees all aspects of financial reporting, budgeting, and investment, ensuring the fiscal health and sustainability of the organization. This critical role involves optimizing resource allocation to support the development and delivery of innovative medicines for underserved patients. The Chief Financial Officer's responsibilities extend to managing financial risks and identifying opportunities for growth through advanced commercial strategies and data-driven insights. Oneil works closely with other executive leaders to align financial objectives with the company's mission of improving patient outcomes and addressing unmet medical needs. Tom Oneil's financial acumen is integral to Azurity Pharmaceuticals' global market engagement and operational efficiency.

Elad Sasson, the Deputy Chief Technology Officer at Azurity Pharmaceuticals, supports the strategic implementation and advancement of technology across the organization. Sasson collaborates on leveraging digital tools and data analytics to enhance the company's commercial strategies and operational capabilities. This role is crucial in driving innovation within the biopharmaceutical sector, particularly in delivering high-quality medicines to underserved patients. The Deputy Chief Technology Officer's focus includes optimizing technological infrastructure to support the diverse portfolio and improve patient engagement. Sasson works to ensure that technology initiatives directly contribute to addressing unmet medical needs and improving patient outcomes globally. Elad Sasson's technical expertise underpins Azurity Pharmaceuticals' commitment to cutting-edge solutions.

Jordan Hunter, the Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) at Azurity Pharmaceuticals, directs strategic initiatives and oversees the Enterprise Project Management Office. Hunter ensures the effective execution of projects critical to developing and delivering innovative medicines for underserved patient populations. This role involves aligning project management methodologies with the company's overall business objectives and commercial strategies. The Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) facilitates cross-functional collaboration, driving efficiency and ensuring timely progress on key programs. Hunter's oversight of the PMO supports the company's mission to improve patient outcomes and address unmet medical needs globally. Jordan Hunter's leadership enhances Azurity Pharmaceuticals' operational agility and strategic execution.

Jordan Lilly, the Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) at Azurity Pharmaceuticals, manages critical strategic projects and enhances operational efficiency. Lilly oversees the Enterprise Project Management Office, ensuring the successful implementation of initiatives aimed at developing and delivering high-quality medicines for underserved patients. This executive function involves coordinating efforts across departments to align with advanced commercial strategies and digital tool integration. The Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) role focuses on optimizing project lifecycles and resource allocation to meet company goals. Lilly's strategic guidance supports Azurity Pharmaceuticals' commitment to improving patient outcomes and addressing unmet medical needs worldwide. Jordan Lilly's contributions are vital to the company's project execution and strategic alignment.

Phillip Shilling, the Chief of Staff & Head of Operations at Azurity Pharmaceuticals, directs operational strategies and ensures seamless execution across the company. Shilling oversees the day-to-day operations, focusing on the efficient development and delivery of innovative, high-quality medicines for underserved patients. This leadership position involves optimizing supply chains, manufacturing processes, and logistical frameworks to support the company's diverse portfolio. The Chief of Staff & Head of Operations role integrates advanced commercial strategies and digital tools to enhance operational reach and effectiveness. Shilling works to ensure that operational excellence directly contributes to improving patient outcomes and addressing unmet medical needs globally. Phillip Shilling's operational leadership is fundamental to Azurity Pharmaceuticals' mission.

Peter Dyke, the Chief People Officer at Azurity Pharmaceuticals, leads human capital strategy and organizational development. Dyke is responsible for cultivating a high-performance culture that supports the company's mission to develop and deliver innovative medicines for underserved patients. This executive role involves attracting, retaining, and developing top talent across all functions, including commercial, R&D, and operations. The Chief People Officer's strategic focus includes implementing programs that enhance employee engagement and align with advanced commercial strategies. Dyke ensures that Azurity Pharmaceuticals' workforce is equipped to drive patient outcomes and address unmet medical needs effectively. Peter Dyke's leadership in people management is essential for the company's sustained growth and success.